Effective  ||| S:0 E:10 ||| JJ
termination  ||| S:10 E:22 ||| NN
of  ||| S:22 E:25 ||| IN
status  ||| S:25 E:32 ||| NN
epilepticus  ||| S:32 E:44 ||| NN
by  ||| S:44 E:47 ||| IN
rational  ||| S:47 E:56 ||| JJ
polypharmacy  ||| S:56 E:69 ||| NN
in  ||| S:69 E:72 ||| IN
the  ||| S:72 E:76 ||| DT
lithium-pilocarpine  ||| S:76 E:96 ||| JJ
model  ||| S:96 E:102 ||| NN
in  ||| S:102 E:105 ||| IN
rats ||| S:105 E:109 ||| NNS
:  ||| S:109 E:111 ||| :
Window  ||| S:111 E:118 ||| NNP
of  ||| S:118 E:121 ||| IN
opportunity  ||| S:121 E:133 ||| NN
to  ||| S:133 E:136 ||| TO
prevent  ||| S:136 E:144 ||| VB
epilepsy  ||| S:144 E:153 ||| NN
and  ||| S:153 E:157 ||| CC
prediction  ||| S:157 E:168 ||| NN
of  ||| S:168 E:171 ||| IN
epilepsy  ||| S:171 E:180 ||| NN
by  ||| S:180 E:183 ||| IN
biomarkers  ||| S:183 E:194 ||| VBG
The  ||| S:194 E:198 ||| DT
pilocarpine  ||| S:198 E:210 ||| JJ
rat  ||| S:210 E:214 ||| NN
model ||| S:214 E:219 ||| NN
,  ||| S:219 E:221 ||| ,
in  ||| S:221 E:224 ||| IN
which  ||| S:224 E:230 ||| WDT
status  ||| S:230 E:237 ||| NN
epilepticus  ||| S:237 E:249 ||| NNS
( ||| S:249 E:250 ||| -LRB-
SE ||| S:250 E:252 ||| NNP
)  ||| S:252 E:254 ||| -RRB-
leads  ||| S:254 E:260 ||| VBZ
to  ||| S:260 E:263 ||| TO
epilepsy  ||| S:263 E:272 ||| VB
with  ||| S:272 E:277 ||| IN
spontaneous  ||| S:277 E:289 ||| JJ
recurrent  ||| S:289 E:299 ||| JJ
seizures  ||| S:299 E:308 ||| NNS
( ||| S:308 E:309 ||| -LRB-
SRS ||| S:309 E:312 ||| NNP
) ||| S:312 E:313 ||| -RRB-
,  ||| S:313 E:315 ||| ,
is  ||| S:315 E:318 ||| VBZ
widely  ||| S:318 E:325 ||| RB
used  ||| S:325 E:330 ||| VBN
to  ||| S:330 E:333 ||| TO
study  ||| S:333 E:339 ||| VB
the  ||| S:339 E:343 ||| DT
mechanisms  ||| S:343 E:354 ||| NNS
of  ||| S:354 E:357 ||| IN
epileptogenesis  ||| S:357 E:373 ||| NN
and  ||| S:373 E:377 ||| CC
develop  ||| S:377 E:385 ||| VB
strategies  ||| S:385 E:396 ||| NNS
for  ||| S:396 E:400 ||| IN
epilepsy  ||| S:400 E:409 ||| JJ
prevention ||| S:409 E:419 ||| NN
.  ||| S:419 E:421 ||| .
SE  ||| S:421 E:424 ||| FW
is  ||| S:424 E:427 ||| VBZ
commonly  ||| S:427 E:436 ||| RB
interrupted  ||| S:436 E:448 ||| VBN
after  ||| S:448 E:454 ||| IN
30-90min  ||| S:454 E:463 ||| CD
by  ||| S:463 E:466 ||| IN
high-dose  ||| S:466 E:476 ||| JJ
diazepam  ||| S:476 E:485 ||| NN
or  ||| S:485 E:488 ||| CC
other  ||| S:488 E:494 ||| JJ
anticonvulsants  ||| S:494 E:510 ||| NN
to  ||| S:510 E:513 ||| TO
reduce  ||| S:513 E:520 ||| VB
mortality ||| S:520 E:529 ||| NN
.  ||| S:529 E:531 ||| .
It  ||| S:531 E:534 ||| PRP
is  ||| S:534 E:537 ||| VBZ
widely  ||| S:537 E:544 ||| RB
believed  ||| S:544 E:553 ||| VBN
that  ||| S:553 E:558 ||| IN
SE  ||| S:558 E:561 ||| NNP
duration  ||| S:561 E:570 ||| NN
of  ||| S:570 E:573 ||| IN
30-60min  ||| S:573 E:582 ||| NNP
is  ||| S:582 E:585 ||| VBZ
sufficient  ||| S:585 E:596 ||| JJ
to  ||| S:596 E:599 ||| TO
induce  ||| S:599 E:606 ||| VB
hippocampal  ||| S:606 E:618 ||| JJ
damage  ||| S:618 E:625 ||| NN
and  ||| S:625 E:629 ||| CC
epilepsy ||| S:629 E:637 ||| NN
.  ||| S:637 E:639 ||| .
However ||| S:639 E:646 ||| RB
,  ||| S:646 E:648 ||| ,
resistance  ||| S:648 E:659 ||| NN
to  ||| S:659 E:662 ||| TO
diazepam  ||| S:662 E:671 ||| VB
develops  ||| S:671 E:680 ||| VBN
during  ||| S:680 E:687 ||| IN
SE ||| S:687 E:689 ||| NNP
,  ||| S:689 E:691 ||| ,
so  ||| S:691 E:694 ||| RB
that  ||| S:694 E:699 ||| IN
an  ||| S:699 E:702 ||| DT
SE  ||| S:702 E:705 ||| NN
that  ||| S:705 E:710 ||| WDT
is  ||| S:710 E:713 ||| VBZ
longer  ||| S:713 E:720 ||| RB
than  ||| S:720 E:725 ||| IN
30min  ||| S:725 E:731 ||| NNP
is  ||| S:731 E:734 ||| VBZ
difficult  ||| S:734 E:744 ||| JJ
to  ||| S:744 E:747 ||| TO
terminate ||| S:747 E:756 ||| VB
,  ||| S:756 E:758 ||| ,
and  ||| S:758 E:762 ||| CC
SE  ||| S:762 E:765 ||| NNP
typically  ||| S:765 E:775 ||| RB
recurs  ||| S:775 E:782 ||| JJ
several  ||| S:782 E:790 ||| JJ
hours  ||| S:790 E:796 ||| NNS
after  ||| S:796 E:802 ||| IN
diazepam ||| S:802 E:810 ||| NN
,  ||| S:810 E:812 ||| ,
thus  ||| S:812 E:817 ||| RB
forming  ||| S:817 E:825 ||| VBG
a  ||| S:825 E:827 ||| DT
bias  ||| S:827 E:832 ||| NN
for  ||| S:832 E:836 ||| IN
studies  ||| S:836 E:844 ||| NNS
on  ||| S:844 E:847 ||| IN
epileptogenesis  ||| S:847 E:863 ||| NN
or  ||| S:863 E:866 ||| CC
antiepileptogenesis ||| S:866 E:885 ||| NN
.  ||| S:885 E:887 ||| .
We  ||| S:887 E:890 ||| PRP
developed  ||| S:890 E:900 ||| VBD
a  ||| S:900 E:902 ||| DT
drug  ||| S:902 E:907 ||| NN
cocktail ||| S:907 E:915 ||| NN
,  ||| S:915 E:917 ||| ,
consisting  ||| S:917 E:928 ||| VBG
of  ||| S:928 E:931 ||| IN
diazepam ||| S:931 E:939 ||| NN
,  ||| S:939 E:941 ||| ,
phenobarbital ||| S:941 E:954 ||| NN
,  ||| S:954 E:956 ||| ,
and  ||| S:956 E:960 ||| CC
scopolamine  ||| S:960 E:972 ||| NNS
that  ||| S:972 E:977 ||| WDT
allows  ||| S:977 E:984 ||| VBZ
complete  ||| S:984 E:993 ||| JJ
and  ||| S:993 E:997 ||| CC
persistent  ||| S:997 E:1008 ||| JJ
SE  ||| S:1008 E:1011 ||| NNP
termination  ||| S:1011 E:1023 ||| NN
in  ||| S:1023 E:1026 ||| IN
the  ||| S:1026 E:1030 ||| DT
lithium-pilocarpine  ||| S:1030 E:1050 ||| JJ
model ||| S:1050 E:1055 ||| NN
.  ||| S:1055 E:1057 ||| .
A  ||| S:1057 E:1059 ||| DT
number  ||| S:1059 E:1066 ||| NN
of  ||| S:1066 E:1069 ||| IN
novel  ||| S:1069 E:1075 ||| NN
findings  ||| S:1075 E:1084 ||| NNS
were  ||| S:1084 E:1089 ||| VBD
obtained  ||| S:1089 E:1098 ||| VBN
with  ||| S:1098 E:1103 ||| IN
this  ||| S:1103 E:1108 ||| DT
cocktail.  ||| S:1108 E:1118 ||| NNP
( ||| S:1118 E:1119 ||| -LRB-
a ||| S:1119 E:1120 ||| LS
)  ||| S:1120 E:1122 ||| -RRB-
In  ||| S:1122 E:1125 ||| IN
contrast  ||| S:1125 E:1134 ||| NN
to  ||| S:1134 E:1137 ||| TO
previous  ||| S:1137 E:1146 ||| JJ
reports  ||| S:1146 E:1154 ||| NNS
with  ||| S:1154 E:1159 ||| IN
incomplete  ||| S:1159 E:1170 ||| JJ
SE  ||| S:1170 E:1173 ||| NNP
suppression ||| S:1173 E:1184 ||| NN
,  ||| S:1184 E:1186 ||| ,
a  ||| S:1186 E:1188 ||| DT
SE  ||| S:1188 E:1191 ||| NNP
of  ||| S:1191 E:1194 ||| IN
60min  ||| S:1194 E:1200 ||| CD
duration  ||| S:1200 E:1209 ||| NN
did  ||| S:1209 E:1213 ||| VBD
not  ||| S:1213 E:1217 ||| RB
induce  ||| S:1217 E:1224 ||| VB
epilepsy ||| S:1224 E:1232 ||| NN
,  ||| S:1232 E:1234 ||| ,
whereas  ||| S:1234 E:1242 ||| IN
epilepsy  ||| S:1242 E:1251 ||| NN
with  ||| S:1251 E:1256 ||| IN
SRS  ||| S:1256 E:1260 ||| NNP
developed  ||| S:1260 E:1270 ||| VBD
after  ||| S:1270 E:1276 ||| IN
90  ||| S:1276 E:1279 ||| CD
or  ||| S:1279 E:1282 ||| CC
120min  ||| S:1282 E:1289 ||| NNP
SE ||| S:1289 E:1291 ||| NNP
;  ||| S:1291 E:1293 ||| :
( ||| S:1293 E:1294 ||| -LRB-
b ||| S:1294 E:1295 ||| LS
)  ||| S:1295 E:1297 ||| -RRB-
by  ||| S:1297 E:1300 ||| IN
comparing  ||| S:1300 E:1310 ||| VBG
groups  ||| S:1310 E:1317 ||| NNS
of  ||| S:1317 E:1320 ||| IN
rats  ||| S:1320 E:1325 ||| NNS
with  ||| S:1325 E:1330 ||| IN
60  ||| S:1330 E:1333 ||| CD
and  ||| S:1333 E:1337 ||| CC
90min  ||| S:1337 E:1343 ||| CD
of  ||| S:1343 E:1346 ||| IN
SE ||| S:1346 E:1348 ||| NNP
,  ||| S:1348 E:1350 ||| ,
development  ||| S:1350 E:1362 ||| NN
of  ||| S:1362 E:1365 ||| IN
epilepsy  ||| S:1365 E:1374 ||| NN
could  ||| S:1374 E:1380 ||| MD
be  ||| S:1380 E:1383 ||| VB
predicted  ||| S:1383 E:1393 ||| VBN
by  ||| S:1393 E:1396 ||| IN
behavioral  ||| S:1396 E:1407 ||| JJ
hyperexcitability  ||| S:1407 E:1425 ||| NN
and  ||| S:1425 E:1429 ||| CC
decrease  ||| S:1429 E:1438 ||| NN
in  ||| S:1438 E:1441 ||| IN
seizure  ||| S:1441 E:1449 ||| NN
threshold ||| S:1449 E:1458 ||| NN
,  ||| S:1458 E:1460 ||| ,
indicating  ||| S:1460 E:1471 ||| VBG
that  ||| S:1471 E:1476 ||| IN
these  ||| S:1476 E:1482 ||| DT
read-outs  ||| S:1482 E:1492 ||| NNS
are  ||| S:1492 E:1496 ||| VBP
suited  ||| S:1496 E:1503 ||| VBN
as  ||| S:1503 E:1506 ||| IN
biomarkers  ||| S:1506 E:1517 ||| NN
of  ||| S:1517 E:1520 ||| IN
epileptogenesis ||| S:1520 E:1535 ||| NNS
;  ||| S:1535 E:1537 ||| :
( ||| S:1537 E:1538 ||| -LRB-
c ||| S:1538 E:1539 ||| LS
)  ||| S:1539 E:1541 ||| -RRB-
CA1  ||| S:1541 E:1545 ||| CD
damage  ||| S:1545 E:1552 ||| NN
was  ||| S:1552 E:1556 ||| VBD
prevented  ||| S:1556 E:1566 ||| VBN
by  ||| S:1566 E:1569 ||| IN
the  ||| S:1569 E:1573 ||| DT
cocktail ||| S:1573 E:1581 ||| NN
,  ||| S:1581 E:1583 ||| ,
but  ||| S:1583 E:1587 ||| CC
rats  ||| S:1587 E:1592 ||| JJ
exhibited  ||| S:1592 E:1602 ||| JJ
cell  ||| S:1602 E:1607 ||| NN
loss  ||| S:1607 E:1612 ||| NN
in  ||| S:1612 E:1615 ||| IN
the  ||| S:1615 E:1619 ||| DT
dentate  ||| S:1619 E:1627 ||| JJ
hilus ||| S:1627 E:1632 ||| NN
,  ||| S:1632 E:1634 ||| ,
which  ||| S:1634 E:1640 ||| WDT
was  ||| S:1640 E:1644 ||| VBD
related  ||| S:1644 E:1652 ||| VBN
to  ||| S:1652 E:1655 ||| TO
development  ||| S:1655 E:1667 ||| NN
of  ||| S:1667 E:1670 ||| IN
epilepsy ||| S:1670 E:1678 ||| NN
.  ||| S:1678 E:1680 ||| .
These  ||| S:1680 E:1686 ||| DT
data  ||| S:1686 E:1691 ||| NNS
demonstrate  ||| S:1691 E:1703 ||| VBP
that  ||| S:1703 E:1708 ||| IN
the  ||| S:1708 E:1712 ||| DT
duration  ||| S:1712 E:1721 ||| NN
of  ||| S:1721 E:1724 ||| IN
SE  ||| S:1724 E:1727 ||| NNP
needed  ||| S:1727 E:1734 ||| VBD
for  ||| S:1734 E:1738 ||| IN
induction  ||| S:1738 E:1748 ||| NN
of  ||| S:1748 E:1751 ||| IN
epileptogenesis  ||| S:1751 E:1767 ||| NN
in  ||| S:1767 E:1770 ||| IN
this  ||| S:1770 E:1775 ||| DT
model  ||| S:1775 E:1781 ||| NN
is  ||| S:1781 E:1784 ||| VBZ
longer  ||| S:1784 E:1791 ||| RB
than  ||| S:1791 E:1796 ||| IN
previously  ||| S:1796 E:1807 ||| RB
thought ||| S:1807 E:1814 ||| VBD
.  ||| S:1814 E:1816 ||| .
